ArticleCureus2026
Dupilumab-Induced Psoriasiform Eruption in an 83-Year-Old Patient.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report describes an 83-year-old female who developed severe psoriasiform lesions suspected to be induced by dupilumab. The patient initially presented with eczematous papules affecting her back, arms, torso, and scalp, and a biopsy confirmed a subacute eczematous process. Treatment with topical, intralesional, and oral steroids failed to show significant improvement. Given the recalcitrant nature of her dermatitis, she was started on dupilumab injections, which initially offered temporary resolution and regression of her existing lesions. However, two weeks after initiating dupilumab treatment, the patient's lesions relapsed and progressively worsened. A repeat biopsy at this time showed psoriasiform epidermal hyperplasia, and dupilumab treatment was stopped. The patient was ultimately transitioned to secukinumab, an IL-17 inhibitor, which resolved her flare.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.